Public Profile

MorphoSys

MorphoSys AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its innovative approach in the field of therapeutic antibodies. Founded in 1992, the company has made significant strides in the development of treatments for cancer and autoimmune diseases, establishing a strong presence in Europe and North America. With a focus on proprietary and partnered drug development, MorphoSys has achieved notable milestones, including the successful launch of its flagship product, Monjuvi (tafasitamab), which targets specific forms of lymphoma. The company’s unique technology platforms, such as its Ylanthus® antibody library, enable the rapid discovery of high-quality therapeutic candidates, positioning MorphoSys as a key player in the biopharmaceutical industry. Through its commitment to advancing healthcare, MorphoSys continues to make impactful contributions to patient care and treatment options.

DitchCarbon Score

How does MorphoSys's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

76

Industry Average

Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

26

Industry Benchmark

MorphoSys's score of 76 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.

99%

Let us know if this data was useful to you

MorphoSys's reported carbon emissions

In 2023, MorphoSys reported total carbon emissions of approximately 18,856,470 kg CO2e. This figure includes Scope 1 emissions of about 101,820 kg CO2e, Scope 2 emissions of approximately 1,340 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled around 18,753,310 kg CO2e. The Scope 3 emissions breakdown reveals major sources, including capital goods (about 10,204,310 kg CO2e), business travel (approximately 1,833,700 kg CO2e), and purchased goods and services (around 3,275,300 kg CO2e). In 2022, MorphoSys's emissions were lower, with total emissions of about 2,073,950 kg CO2e, comprising Scope 1 emissions of approximately 103,350 kg CO2e, Scope 2 emissions of about 1,060,640 kg CO2e, and Scope 3 emissions of around 1,072,960 kg CO2e. Despite these figures, MorphoSys has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of defined reduction strategies suggests a need for further transparency regarding their long-term climate goals and actions.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
103,350
000,000
Scope 2
1,060,640
0,000
Scope 3
1,072,960
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. MorphoSys's primary industry is Other business services (74), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for MorphoSys is in DE, which has a medium grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

MorphoSys is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

NIOX Group Plc

GB
Health and social work services (85)
Updated 4 days ago

Zealand Pharma A/S

DK
Health and social work services (85)
Updated 4 days ago

Alk

DK
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Gilead Sciences

US
Research and development services (73)
Updated 4 days ago

Consort Medical plc

GB
Health and social work services (85)
Updated 4 days ago

Almirall

ES
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers